Baxter International Inc (BAX) Shares Bought by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC increased its position in Baxter International Inc (NYSE:BAX) by 4.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,666,746 shares of the medical instruments supplier’s stock after buying an additional 73,771 shares during the period. Parametric Portfolio Associates LLC owned 0.31% of Baxter International worth $104,588,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Toronto Dominion Bank lifted its position in shares of Baxter International by 8.6% in the third quarter. Toronto Dominion Bank now owns 212,015 shares of the medical instruments supplier’s stock worth $13,304,000 after buying an additional 16,835 shares in the last quarter. Johnson Financial Group Inc. lifted its position in shares of Baxter International by 15.5% in the third quarter. Johnson Financial Group Inc. now owns 21,038 shares of the medical instruments supplier’s stock worth $1,320,000 after buying an additional 2,825 shares in the last quarter. Bahl & Gaynor Inc. lifted its position in shares of Baxter International by 24.8% in the second quarter. Bahl & Gaynor Inc. now owns 20,940 shares of the medical instruments supplier’s stock worth $928,000 after buying an additional 4,162 shares in the last quarter. Veritas Asset Management LLP lifted its position in shares of Baxter International by 2.3% in the second quarter. Veritas Asset Management LLP now owns 10,179,102 shares of the medical instruments supplier’s stock worth $616,243,000 after buying an additional 227,343 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its position in shares of Baxter International by 35.8% in the third quarter. Canada Pension Plan Investment Board now owns 1,413,054 shares of the medical instruments supplier’s stock worth $88,669,000 after buying an additional 372,500 shares in the last quarter. Institutional investors own 84.18% of the company’s stock.

A number of brokerages have issued reports on BAX. Bank of America restated a “hold” rating on shares of Baxter International in a research report on Wednesday, November 22nd. Royal Bank of Canada restated a “hold” rating and set a $66.00 price objective on shares of Baxter International in a research report on Wednesday, November 22nd. Stifel Nicolaus restated a “hold” rating and set a $65.00 price objective on shares of Baxter International in a research report on Thursday, October 26th. Barclays upped their price objective on Baxter International from $70.00 to $73.00 and gave the company an “overweight” rating in a research report on Thursday, October 26th. Finally, Morgan Stanley upped their price objective on Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $67.46.

In other news, Director Third Point Llc sold 5,000,000 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $64.23, for a total transaction of $321,150,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jeanne K. Mason sold 33,350 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the transaction, the senior vice president now directly owns 124,609 shares in the company, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

Shares of Baxter International Inc (BAX) opened at $65.33 on Friday. Baxter International Inc has a 52-week low of $43.81 and a 52-week high of $66.18. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.22 and a current ratio of 2.80. The stock has a market capitalization of $35,588.43, a P/E ratio of 26.99, a price-to-earnings-growth ratio of 2.18 and a beta of 0.69.

Baxter International (NYSE:BAX) last released its earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The firm had revenue of $2.71 billion for the quarter, compared to analysts’ expectations of $2.66 billion. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.56 earnings per share. equities research analysts predict that Baxter International Inc will post 2.43 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, January 2nd. Stockholders of record on Friday, December 1st will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Thursday, November 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.98%. Baxter International’s dividend payout ratio is 34.41%.

TRADEMARK VIOLATION NOTICE: “Baxter International Inc (BAX) Shares Bought by Parametric Portfolio Associates LLC” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2017/12/17/baxter-international-inc-bax-shares-bought-by-parametric-portfolio-associates-llc.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply